740 Y-P

740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone[1].

C([C@@H](C(N[C@@H](CC1=CC=CC=C1)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC=2C=3C(NC2)=CC=CC3)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N[C@@H](CC4=CC=C(OP(=O)(O)O)C=C4)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CO)=O)CCSC)=O)CC(O)=O)=O)CCSC)=O)=O)=O)=O)CC(O)=O)=O)CO)=O)CCCCN)=O)CCCCN)=O)=O)CCCCN)=O)CCSC)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CC(N)=O)=O)CCC(N)=O)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCCNC(=N)N)N)=O)CCC(N)=O)=O)[C@H](CC)C)=O)CCCCN)=O)[C@H](CC)C)=O)C=5C=6C(NC5)=CC=CC6

[1]Derossi D, et al. Stimulation of mitogenesis by a cell-permeable PI 3-kinase binding peptide.|[2]Xiaoli Feng, et al. Graphene Oxide Induces p62/SQSTM-dependent Apoptosis Through the Impairment of Autophagic Flux and Lysosomal Dysfunction in PC12 Cells. Acta Biomater. 2018 Nov;81:278-292.|[3]Zhiqing Sun, et al. GABAB Receptor-Mediated PI3K/Akt Signaling Pathway Alleviates Oxidative Stress and Neuronal Cell Injury in a Rat Model of Alzheimer's Disease. J Alzheimers Dis. 2020;76(4):1513-1526.ACS Omega. 2022.|Acta Biomater. 2018 Nov;81:278-292. |Aging (Albany NY). 2021 Sep 27;13(18):22502-22515.|Am J Transl Res. 2021 Apr 15;13(4):2060-2076.|Apoptosis. 2024 Jun 2.|Apoptosis. 2024 Sep 6.|Arch Biochem Biophys. 2023 May 22, 109645.|Arch Pharm Res. 2021 Jan 27.|Biochem Biophys Res Commun. 2022 May 21;605:162-170.|Biochem Biophys Res Commun. 2023 Jun 3.|Biochem Biophys Res Commun. 2024 Apr 23:149983.|Bioengineered. 2021 Nov 30.|Bioengineered. 2022 Apr;13(4):10047-10060.|Biol Reprod. 2023 Aug 21;ioad097.|Biomaterials. 2019 Feb;194:57-72. |Biomed Pharmacother. 2020 Nov;131:110689.|Biomed Pharmacother. 2024 Oct 22:180:117560.|bioRxiv. 2023 Mar 25.|BMC Cancer. 2022 Jun 18;22(1):671.|BMC Cancer. 2023 Jul 5;23(1):628.|BMC Med. 2022 Dec 8;20(1):475.|Braz J Med Biol Res. 2024 Aug 19:57:e13796.|Cancer Med. 2022 Nov 6.|Cancers (Basel). 2023 Mar 28.|Carbon. 2023 Jan 25, 217, 118617.|Cell Biochem Biophys. 2024 Oct 14.|Cell Biosci. 2019 Aug 27;9:68.|Cell Commun Signal. 2020 Aug 24;18(1):131.|Cell Death Dis. 2021 Sep 13;12(9):845.|Cell Mol Life Sci. 2024 Mar 13;81(1):133.|Cell Prolif. 2022 Sep 26;e13342.|Cell Rep. 2021 Nov 16;37(7):110007.|Cell Signal. 2020 Jul;71:109606.|Cells. 2023 Jan 3;12(1):194.|Chin Med. 2022 Sep 29;17(1):115.|Clin Med Insights-On. 2021 May 5.|Contrast Media Mol Imaging. 14 Jul 2022.|Cytokine. 2021 Dec 1;150:155776.|Dis Markers. 02 Sep 2021.|Drug Dev Res. 2022 Apr 26.|Drug Dev Res. 2022 Sep 6.|Epigenetics. 2023 Dec;18(1):2239607.|Eur J Pharmacol. 2023 Jun 26;175863.|Eur J Pharmacol. 2024 Feb 7:968:176401.|Eur J Pharmacol. 2024 Sep 10:176824.|Eur J Pharmacol. 2024 Sep 10:176991.|Exp Cell Res. 2019 Dec 15;385(2):111691.|Exp Eye Res. 2022 Nov 24;109335.|Exp Mol Med. 2023 May 1.|Exp Ther Med. July 15, 2021.|Fish Shellfish Immunol. 2021 Dec 28;120:648-657.|Free Radic Biol Med. 2023 Oct 10;209(Pt 1):55-69.|Front Biosci (Landmark Ed). 2024 Aug 19;29(8):289.|Front Pharmacol. 2020 Feb 25;11:114. |Front Pharmacol. 2021 Jul 15;12:667644.|Gene Ther. 2024 Sep 21.|Genes (Basel). 2023 Apr 20, 14(4), 944.|Genes Dis. 1 July 2021.|Genomics. 2023 May 5;110636.|Glia. 2022 Nov 23.|Heliyon. 2024 Aug 20;10(17):e36579.|Heliyon. 2024 Jul 10;10(14):e34397.|Heliyon. 2024 July 10.|Heliyon. 2024 Jun 10;10(12):e32802.|Heliyon. 2024 May 31.|In Vitro Cell Dev Biol Anim. 2022 Jun 15.|Inflammopharmacology. 2022 Nov 19.|Int Immunopharmacol. 2023 Jul 9;122:110579.|Int Immunopharmacol. 2023 Sep 5;124(Pt A):110876.|Int Immunopharmacol. 2024 Apr 15:133:112005.|Int Immunopharmacol. 2024 Jul 26:139:112717.|Int Immunopharmacol. 2024 May 17:134:112241.|Int J Biol Macromol. 2023 Jun 13;125373.|Int J Biol Macromol. 2024 Sep 10:135547.|Int J Mol Med. 2021 Feb;47(2):688-698.|Int J Mol Med. 2021 May;47(5):67.|Int J Mol Med. 2023 May;51(5):40.|Int J Mol Sci. 2023 May 19, 24(10), 9000.|Int J Oncol. 2021 May 14.|Int J Oncol. 2021 May;58(5):23.|Ir J Med Sci. 2022 May 4.|iScience. 2024 Jan 12|J Agric Food Chem. 2022 Dec 21;70(50):15804-15817.|J Cell Mol Med. 2024 Jul;28(13):e18386.|J Cell Physiol. 2024 Mar 22.|J Clin Invest. 2022 Nov 22;e153470.|J Clin Lab Anal. 2022 Nov 8;e24720.|J Dairy Sci. 2022 Feb 2;S0022-0302(22)00059-5.|J Ethnopharmacol. 2021 Aug 11;281:114438.|J Ethnopharmacol. 2023 Dec 27:117628.|J Ethnopharmacol. 2024 Jan 20:117768.|J Ethnopharmacol. 2024 Oct 4:118910.|J Exp Clin Cancer Res. 2020 Jun 30;39(1):123.|J Exp Clin Cancer Res. 2021 Aug 12;40(1):255.|J Funct Foods. 2023 Oct, 109, 105770.|J Headache Pain. 2022 Aug 10;23(1):98.|J Hepatocell Carcinoma. 2021 Nov 3;8:1323-1338.|J Mol Histol. 2023 Sep 30.|J Nutr Biochem. 2021 Oct 13;108882.|J Nutr Biochem. 2024 Jul 16:109702.|J Pharm Pharmacol. 2022 Jul 5;rgac047.|J Transl Med. 2021 Feb 10;19(1):62.|J Transl Med. 2023 Nov 16;21(1):817.|Korean J Physiol Pharmacol. 2022 Nov 1;26(6):541-556.|Life Sci. 2021 Jan 25;119107.|Life Sci. 2019 Sep 15;233:116696.|Mater Today Bio. 2022 Jul 1;16:100344.|Mol Biol Rep. 2022 Nov 12.|Mol Cancer. 2022 May 10;21(1):112.|Mol Cell Biochem. 2022 Apr 1.|Mol Cell Biochem. 2022 Feb 19.|Mol Cell Proteomics. 2023 Jul 31;100628.|Mol Med Rep. 2021 Jan;23(1):76.|Mol Med. 2023 Oct 3;29(1):133.|Mol Neurobiol. 2024 Sep 23.|Nat Commun. 2024 Sep 12;15(1):7996.|Naunyn Schmiedebergs Arch Pharmacol. 2023 Aug 9.|Neurogastroenterol Motil. 2020 Oct;32(10):1514-1528.|Noncoding RNA Res. 2024 Nov 12.|Onco Targets Ther. 2019 Dec 4;12:10639-10650.|Oncol Lett. 2023 Apr 13, 25(6): 224.|Oncol Lett. 2023 Nov 15.|Oncol Lett. September 28, 2021.|Oncol Rep. 2020 Mar;43(3):919-929.|Oncol Rep. 2021 Mar 16.|Oncol Rep. 2022 Oct;48(4):169.|OncoTargets and Therapy Dovepress. 2019 Oct 16;12:8537-8552.|Oral Dis. 2024 Jan 15.|Oxid Med Cell Longev. 2021 Mar 31.|Pathol Res Pract. 2023 Jul 27, 154717.|Pharm Biol. 2022 Dec;60(1):75-86.|Phytomedicine. 2023 May 13, 154873.|Phytomedicine. 2023 Sep 22, 155117.|Phytomedicine. 28 July 2022, 154360.|Phytomedicine. May 2022, 154014.|Phytother Res. 2023 Apr 28.|Phytother Res. 2024 May 2.|PLoS One. 2024 Oct 16;19(10):e0311419.|PLoS One. 2024 Sep 27;19(9):e0311143.|Research Square Preprint. 2023 Apr 13.|Research Square Preprint. 2023 Aug 10.|Research Square Preprint. 2024 Mar 25.|Research Square Preprint. 2024 May 2.|Research Square Print. 2022 May.|Respir Physiol Neurobiol. 2020 Oct;281:103496.|Sci Rep. 2021 Sep 29;11(1):19268.|Sci Rep. 2023 Jul 21;13(1):11795.|Sci Rep. 2024 Aug 30;14(1):20231.|Sci Rep. 2024 Sep 5;14(1):20802.|Technol Cancer Res Treat. Jan-Dec 2020;19:1533033820957023. |Theranostics. 2024 Jul 8;14(11):4278-4296.|Toxicol Appl Pharmacol. 2020 Dec 15;409:115335.|Toxicol Appl Pharmacol. 9 March 2022, 115971.|Toxicol In Vitro. 2022 Apr;80:105328.|Traditional Medicine Research. 2020 May.|Viruses. 2023 Jul 28, 15(8), 1646.|World J Gastrointest Oncol. 2023 Oct 15.|BMC Complement Med Ther. 2023 Aug 22;23(1):295.